Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2024-11-27 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
关于“泰林转债”赎回实施的第四次提示性公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the conditional redemption (early call) of a convertible bond issued by Zhejiang Tailin Biotechnology Co., Ltd. It includes specifics about the redemption price, dates, conditions triggering the redemption, and procedural details. It references regulatory approvals and legal opinions but does not contain financial statements or quarterly/yearly financial results. The document is primarily an official notice about a capital market event (bond redemption and subsequent delisting of the bond from the exchange). It is not an annual or interim report, earnings release, or management discussion. It is not a simple brief announcement but a comprehensive update on financing activity related to convertible bonds. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-11-27 Chinese
关于“泰林转债”赎回实施的第三次提示性公告
Delisting Announcement Classification · 95% confidence The document is a detailed announcement regarding the conditional redemption of a convertible bond issued by Zhejiang Tailin Biotechnology Co., Ltd. It includes specific dates, redemption prices, terms, and procedures related to the bond redemption and subsequent delisting of the bond from the Shenzhen Stock Exchange. The document also references board and supervisory committee meeting resolutions and legal opinions related to the redemption. It is not a financial report, earnings release, or management discussion but a formal notice about a capital market event involving bond redemption and delisting. Therefore, the most appropriate classification is a Delisting Announcement (DLST) because the bond will be delisted after redemption, and the document serves as the official notice of this event.
2024-11-26 Chinese
关于控股股东、实际控制人及其一致行动人持股比例被动稀释超过1%的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding a passive dilution of shareholding percentage by the controlling shareholders and their concerted parties due to convertible bonds being converted into shares. It details the shareholding changes, percentages before and after the dilution, and confirms no change in control or governance structure. The document is a formal disclosure of a change in major shareholding levels, specifically noting a passive dilution exceeding 1%. There is no financial report, earnings data, or management discussion. The content fits the definition of a Major Shareholding Notification (MRQ) as it notifies the market of changes in significant share ownership levels crossing thresholds.
2024-11-26 Chinese
关于“泰林转债”赎回实施的第二次提示性公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding the conditional redemption of its convertible bonds "Tailin Convertible Bonds". It details the redemption price, conditions triggering the redemption, timeline for trading suspension, redemption procedures, and related legal and regulatory approvals. The document includes specific dates, bond codes, regulatory approvals from the China Securities Regulatory Commission, and references to the bond issuance prospectus. It also mentions the bond will be delisted from the Shenzhen Stock Exchange after redemption. The content is focused on the redemption and delisting of convertible bonds, which is a capital structure change and financing update. It is not a full financial report, earnings release, or management discussion. It is not a simple announcement of a report publication but a substantive update on financing and capital structure. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-11-25 Chinese
关于“泰林转债”赎回实施的第一次提示性公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding the conditional redemption of its convertible bonds "Tailin Convertible Bonds" ("泰林转债"). It details the redemption price, conditions triggering the redemption, timeline for redemption, and related procedural information. It also mentions that after redemption, the convertible bonds will be delisted from the Shenzhen Stock Exchange. The document includes references to board and supervisory committee meetings approving the redemption, legal opinions, and verification opinions from securities firms. The content is focused on the redemption and delisting process of convertible bonds, not a financial report or earnings release. It is a formal notice about capital structure changes and financing activities related to convertible bonds. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is sufficient and contains detailed information about the redemption event, not just a brief notice or a report publication announcement.
2024-11-22 Chinese
第四届董事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of a board meeting resolution by Zhejiang Tailin Biotechnology Co., Ltd. It details the board's decision to approve the early redemption of convertible bonds, including voting results and procedural authorizations. The document is short (995 characters) and serves as a formal announcement of a board decision rather than a full report or financial statement. It does not contain financial data or detailed management discussion, nor is it a regulatory certification or a proxy solicitation. The content fits best under Board/Management Information (MANG) as it relates to a board resolution and management authorization regarding bond redemption.
2024-11-21 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.